Cytokine Gene Expression and Treatment Impact on MRI Outcomes in Jordanian Patients with Multiple Sclerosis

Background: Central nervous system autoimmune disorders, like multiple sclerosis (MS), are chronic conditions where cytokines contribute significantly to the regulation of inflammation. The diagnosis, progression, and treatment effectiveness of MS are assessed through laboratory tests and clinical e...

Full description

Saved in:
Bibliographic Details
Main Authors: Sawsan I. Khdair, Mohammed Waleed, Alaa M. Hammad, Lubna Al-Khareisha, Tariq Jaber, Majd Ayash, Frank Scott Hall
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Life
Subjects:
Online Access:https://www.mdpi.com/2075-1729/15/6/859
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Central nervous system autoimmune disorders, like multiple sclerosis (MS), are chronic conditions where cytokines contribute significantly to the regulation of inflammation. The diagnosis, progression, and treatment effectiveness of MS are assessed through laboratory tests and clinical evaluation, as well as imaging. Method: This study included 40 healthy individuals as a control group and 75 MS patients, divided into two groups: 45 MS patients receiving fingolimod treatment (MSW) and 30 patients taking other medications (MSOs). Blood samples (3 mL) were collected from all participants, and the mRNA relative expression of cytokine genes (<i>IL-1β</i>, <i>TNF-α</i>, <i>IL-6</i>, and <i>INF-γ</i>) was measured. Additionally, MRI images of MS patients undergoing fingolimod or other treatments were analyzed. Results: The MSO patient group displayed higher mRNA expressions of <i>IL-1β</i>, <i>TNF-α</i>, <i>IL-6</i>, and <i>INF-γ</i> compared to the control group. Furthermore, <i>TNF-α</i>, <i>IL-6</i>, and <i>INF-γ</i> expressions were elevated in the MSO group compared to the MSW group. MRI scans showed significant improvement in MS patients taking fingolimod compared to those receiving other medications. Conclusions: Fingolimod demonstrated greater effectiveness in improving MS patients’ conditions, possibly due to its impact on cytokine expression.
ISSN:2075-1729